Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion evidence source_evidence_literature NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion SIO_000772 15330799 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion wasDerivedFrom befree-2016 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion wasGeneratedBy ECO_0000203 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- befree-2016 importedOn "2016-02-19" NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.